What is HC Wainwright’s Estimate for BOLT Q3 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Bolt Biotherapeutics in a research report issued to clients and investors on Monday, October 20th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($5.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2025 earnings at ($4.93) EPS and FY2026 earnings at ($17.96) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Thursday, August 14th. The company reported ($4.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.94. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.82 million.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Lake Street Capital raised their price objective on Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a research note on Friday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $34.00.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $5.78 on Wednesday. The company has a 50-day moving average of $5.39 and a 200-day moving average of $6.00. The firm has a market cap of $11.09 million, a price-to-earnings ratio of -0.22 and a beta of 0.91. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.56. Bolt Biotherapeutics has a twelve month low of $4.59 and a twelve month high of $14.36.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.